Technique may predict treatment outcomes in MM

Print Friendly, PDF & Email


Bone marrow smear
showing multiple myeloma
A cell-measuring technique can help predict how multiple myeloma (MM) patients will respond to different therapies, according to research published in Nature Communications. The technique involves a microfluidic device known as a serial suspended microchannel resonator (sSMR). The sSMR measures cell mass and allows researchers to calculate... [Read Article]
Print Friendly, PDF & Email

CAR T-cell therapy on fast track with FDA, EMA

Print Friendly, PDF & Email


Micrograph showing
multiple myeloma
A chimeric antigen receptor (CAR) T-cell therapy, bb2121, has received breakthrough therapy designation from the US Food and Drug Administration (FDA) and was granted access to the European Medicines Agency’s (EMA’s) PRIority MEdicines (PRIME) program. The CAR T-cell therapy is designed to target B-cell maturation antigen in previously treated... [Read Article]
Print Friendly, PDF & Email

FDA grants product breakthrough designation for MM

Print Friendly, PDF & Email


Monoclonal antibodies
Photo by Linda Bartlett
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to GSK2857916, an anti-B-cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent monomethyl auristatin-F via a non-cleavable linker. The designation is for GSK2857916 as monotherapy for patients with multiple myeloma (MM) who have... [Read Article]
Print Friendly, PDF & Email